Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz

Franco Maggiolo, Marco Migliorino, Renato Maserati, Angelo Pan, Marco Rizzi, Grazia Pravettoni, Laura Rizzi, Fredy Suter

Research output: Contribution to journalArticle

Abstract

Current antiretroviral drugs cannot eradicate HIV infections, and persons living with HIV are often faced with very demanding daily therapeutic schedules that can induce poor adherence. More conveniently dosed and patient-friendly regimens are needed. We investigated, in this 48-week pilot study, a once-a-day highly active antiretroviral therapy regimen of didanosine, lamivudine and efavirenz. Seventy-five consecutive antiretroviral-naive subjects were enrolled. Over the 48-week period, plasma HIV-RNA levels declined sharply, with a median decrease at the end of the observation time >3.4 log copies/ml. The proportion of patients achieving a plasma HIV-RNA level below the limit of detection (50 copies/ml) was 77% (intention to treat analysis) at the end of the study period. The mean CD4 cell count increased steadily over time from 251 to 459 cells/μl. Antiviral efficacy was similar in patients with a baseline HIV-RNA level above or below 100 000 copies/ml. However, patients with a baseline CD4 cell count

Original languageEnglish
Pages (from-to)249-253
Number of pages5
JournalAntiviral Therapy
Volume6
Issue number4
Publication statusPublished - 2001

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology

Cite this

Maggiolo, F., Migliorino, M., Maserati, R., Pan, A., Rizzi, M., Pravettoni, G., Rizzi, L., & Suter, F. (2001). Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antiviral Therapy, 6(4), 249-253.